Albireo Pharma Future Growth
Future criteria checks 2/6
Albireo Pharma is forecast to grow earnings and revenue by 62.9% and 51.1% per annum respectively while EPS is expected to grow by 61.4% per annum.
Key information
62.9%
Earnings growth rate
61.4%
EPS growth rate
Biotechs earnings growth | 0% |
Revenue growth rate | 51.1% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 24 Feb 2023 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 248 | -5 | N/A | N/A | 5 |
12/31/2024 | 128 | -102 | N/A | N/A | 5 |
12/31/2023 | 61 | -144 | N/A | N/A | 7 |
12/31/2022 | 35 | -159 | N/A | N/A | 7 |
9/30/2022 | 57 | -131 | -116 | -115 | N/A |
6/30/2022 | 51 | -36 | -114 | -113 | N/A |
3/31/2022 | 45 | -33 | -109 | -108 | N/A |
12/31/2021 | 41 | -34 | -108 | -108 | N/A |
9/30/2021 | 11 | -48 | -122 | -122 | N/A |
6/30/2021 | 9 | -136 | -121 | -120 | N/A |
3/31/2021 | 9 | -120 | -112 | -112 | N/A |
12/31/2020 | 8 | -108 | -101 | -101 | N/A |
9/30/2020 | 12 | -90 | -85 | -85 | N/A |
6/30/2020 | 11 | -82 | -73 | -73 | N/A |
3/31/2020 | 11 | -78 | -64 | -63 | N/A |
12/31/2019 | 10 | -63 | -53 | -53 | N/A |
9/30/2019 | 4 | -71 | -51 | -51 | N/A |
6/30/2019 | 3 | -63 | -47 | -47 | N/A |
3/31/2019 | 2 | -61 | -41 | -41 | N/A |
12/31/2018 | 13 | -46 | -27 | -27 | N/A |
9/30/2018 | 12 | -35 | -25 | -25 | N/A |
6/30/2018 | 12 | -28 | -20 | -20 | N/A |
3/31/2018 | 11 | -19 | -18 | -18 | N/A |
12/31/2017 | 0 | -24 | -28 | -28 | N/A |
9/30/2017 | 3 | -31 | -26 | -26 | N/A |
6/30/2017 | 3 | -28 | -25 | -25 | N/A |
3/31/2017 | 11 | -20 | -15 | -15 | N/A |
12/31/2016 | 11 | -16 | -9 | -9 | N/A |
9/30/2016 | 13 | -5 | -1 | -1 | N/A |
6/30/2016 | 13 | -4 | N/A | 1 | N/A |
3/31/2016 | 5 | -8 | N/A | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALBO * is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ALBO * is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ALBO * is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ALBO *'s revenue (51.1% per year) is forecast to grow faster than the MX market (6.2% per year).
High Growth Revenue: ALBO *'s revenue (51.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ALBO *'s Return on Equity is forecast to be high in 3 years time